Effect of Empagliflozin Metformin with Clomiphene Citrate versus Metformin with Clomiphene Citrate on cases of Polycystic Ovary Syndrome
Abstract
Background: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age associated with long-term metabolic and cardiovascular consequences. Aim and objectives: In this research, we aimed to assess the impact of Empagliflozin Metformin with Clomiphene Citrate versus Metformin with Clomiphene Citrate on weight reduction and its impact on folliculometry and ovarian volume in cases of Polycyctic Ovary Syndrome. Subjects and Methods: This was a randomized clinical trial; in which 150 Patients were being randomly assigned into two equal groups; Group A: 75 cases received empagliflozin metformin 12.5/500 mg Continously once daily plus clomiphene citrate 50 mg twice daily for 3 cycles cycles from day 2 of the natural or the withdrawal cycle for 5 days. Group B: 75 cases received metformin 500 mg continously once daily plus clomiphene citrate 50 mg twice daily for 3 cycles from day 2 of the natural or the withdrawal cycle for 5 days. Results: there was a significant variation between the two studied groups regarding BMI hip circumference ovarian characteristics (ovarian volume and AFC), FBG, fasting insulin and ovulation rate. Conclusion: Empagliflozin metformin with clomiphene citrate treatment had beneficial effects on anthropometric parameters (BMI and hip circumference), ovarian characteristics (ovarian volume and AFC), FBG, fasting insulin and ovulation rate in women with PCOS compared to metformin with clomiphene citrate, but no…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 150 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.